Is canakinumab FDA approved for the treatment of gout?

Updated: Jan 26, 2021
  • Author: Bruce M Rothschild, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

In 2010, an 8-week, single-blind, double-dummy, dose-ranging study showed that the selective IL-1β antibody canakinumab yielded fast and lasting relief of pain in patients with acute gouty arthritis flares refractory to treatment with NSAIDs or colchicine. [185] However, in June 2011, canakinumab was denied approval by the FDA. [186] (See FDA Panel Says No to Canakinumab for Gout Attacks.)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!